Integrating Supportive Care Into Everyday Practice

News
Video

Being proactive and quickly identifying when a patient may need the supportive care team is the best way to integrate this field into whole-person care.

Declan Walsh, MD, spoke about the importance of integrating supportive care into regular check-ins and follow-ups with other oncology specialties. Supportive and palliative care as a field may come in many different forms; Walsh emphasized how important it is for clinicians to know about the benefits and opportunities of this space.

Walsh gave numerous ways on how this specialty can be integrated into everyday care, including being involved in tumor boards and having a comprehensive care team. Additionally, he would like early recognition of a patient’s needs so that supportive care can be brought in at an appropriate time.

Walsh is chair of the Department of Supportive Oncology at Atrium Health Levine Cancer.

Transcript:

[Supportive care is] a 2-way street. Those of us who are interested in providing supportive oncology services should be very willing to engage in the sharp end of cancer care so that we are accessible, we respond quickly, and we are part of the comprehensive clinical care team. [We are] building these ideas into, for example, tumor boards, where at a tumor board meeting, not only is radiation oncology represented in medical oncology but also supportive oncology. We take a comprehensive view of that person’s case and of their management of that disease. Then, from our colleagues’ point of view, whether they’re surgical oncologists or medical oncologists, there’s been a cultural change. People are much more appreciative of the services now and much more understanding of their importance. What we would like to see is early recognition of the patient’s needs by our clinician colleagues so that the supportive oncology services can get in right at the beginning of the illness trajectory [and] we can have the greatest impact and the best collaboration with all our clinical colleagues, irrespective of what their discipline may be.

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content